RSP-1502 / Respirion Pharma - LARVOL DELTA

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Respirion Pharmaceuticals Pty Ltd | N=52 ➔ 72 | Trial completion date: Apr 2025 ➔ Dec 2025 | Trial primary completion date: Apr 2025 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (clinicaltrials.gov) - P1/2 | N=52 | Recruiting | Sponsor: Respirion Pharmaceuticals Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (clinicaltrials.gov) - P1/2 | N=52 | Not yet recruiting | Sponsor: Respirion Pharmaceuticals Pty Ltd | Phase classification: P1b ➔ P1/2

Phase classification • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (clinicaltrials.gov) - P1b | N=52 | Not yet recruiting | Sponsor: Respirion Pharmaceuticals Pty Ltd

New P1 trial • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases